Her2-Pozitif Erken Evre Meme Kanserinde Neoadjuvan Tedavi Sonrası Rezidual Hastalığa Yaklaşım

Cortazar P, Zhang J, Untch M, et al. "Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis." Lancet. 2014;384,164-172. doi:10.1016/S0140-6736(13)62422-8

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-628. doi:10.1056/NEJMoa1814017)

Geyer, C. E. Jr., Untch, M., Huang, C.-S., et al. (for the KATHERINE Study Group). Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine, 2025; 392(3), 249-257. doi:10.1056/NEJMoa2406070

Carmona FJ, Montemurro F, Kannan S, et al. Pharmacology and Therapeutics. 2016;158:63–70. Doi:10.1016/J.phermthera.2015.11.013

Chia S, Gandhi S, Joy AA, et al. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol. 2015;22:33–48. doi:10.3747/co.22.2393

Molly AN, Worapul N, Shiuh-Wen L, et al. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. Cancer and Metastasis Rewiews 2021;40(2):519-536. doi:10.1007/s10555-021-09968-0